What are the fundraising trends in the alternative protein market?
In our alternative protein market deck, you will find everything you need to understand the market
SUMMARY
We analyzed every publicly disclosed equity round raised by pure-play alternative protein companies between January 2024 and May 2026. The dataset keeps only disclosed equity rounds of $300K or more, excludes debt, grants and undisclosed-amount rounds, and covers plant-based meat, plant-based dairy, plant-based eggs, fermentation proteins, cultivated meat and cultivated seafood.
The alternative protein market became materially smaller on the clean full-year comparison. Eligible disclosed equity funding fell from about $729M across 24 deals in 2024 to about $365M across 22 deals in 2025, which means the reset came mostly through smaller rounds rather than a collapse in deal count.
Early 2026 looks healthier than early 2025, but the rebound is narrow. From January through May 2026, the market raised about $114M across 10 deals, compared with about $62M across 5 deals over the comparable 2025 period.
Fermentation proteins are the center of gravity. They captured about 66% of 2024 capital, about 56% of 2025 capital, and about 78% of year-to-date 2026 capital, making fermentation the only category with both repeated deal activity and large-check investor conviction.
The market remains highly concentrated. In year-to-date 2026, the top three rounds, Verley, Standing Ovation and Planetary, account for about 69% of all disclosed capital. Without those three rounds, the market would look much smaller.
Round sizes are still compressed versus 2024. The median eligible round fell from about $23M in 2024 to about $9M in 2025, and sits around $6.5M in year-to-date 2026. That is the clearest sign that the average funded company is raising more cautiously than in the previous cycle.
Capital is moving toward follow-on companies rather than new formation. First financings represented about 21% of deals in 2024, about 9% in 2025, and about 10% in year-to-date 2026, but they captured only around 2% to 3% of capital in each period.
Europe has become the strongest regional funding center. Europe represented about 41% of 2024 capital, about 66% of 2025 capital, and about 79% of year-to-date 2026 capital, while North America fell sharply as a share of disclosed funding.
Plant-based meat is not dead, but generic plant-based meat is weak. The funded plant-based meat companies that still attract capital tend to show differentiated texture, localized product-market fit, foodservice relevance, or manufacturing advantages.
The practical interpretation is that the alternative protein market has shifted from broad category enthusiasm to evidence-sensitive survivor selection. Investors are still funding the market, but they now prefer specific bottleneck solutions around protein functionality, fermentation scale, regulatory readiness, cost progress and supply-chain fit.
This chart, featured in our alternative protein market deck, shows revenue breakdown by customer segment in the alternative protein market
Is more or less capital going into the alternative protein market?
Less capital is going into the alternative protein market on the clean full-year comparison, but early 2026 is stronger than the comparable period in 2025. The market raised about $729M across 24 eligible deals in 2024, then fell to about $365M across 22 eligible deals in 2025. From January through May 2026, it has raised about $114M across 10 deals, compared with about $62M across 5 deals over the same period in 2025.
The most important structural signal is the 2024-to-2025 decline. Deal count barely moved, from 24 to 22, but total capital fell by roughly half. That means the alternative protein market did not stop funding companies; it stopped funding them at the same average size.
The year-to-date 2026 comparison is more encouraging. Capital is up versus the same 2025 window, and deal count has doubled. That suggests the market is not continuing to deteriorate at the same pace.
The caveat is concentration. The top three 2026 rounds account for about 69% of year-to-date capital, so the rebound depends heavily on Verley, Standing Ovation and Planetary. The honest interpretation is that capital is returning selectively, not broadly.
The practical takeaway is that the alternative protein market is below its 2024 funding level, but no longer looks frozen. It is reopening around a narrower set of technical, ingredient-led and fermentation-heavy companies.
Is alternative protein funding driven by more deals or larger rounds?
Alternative protein funding is being driven more by larger selected rounds than by broad-based deal expansion, although early 2026 does show more deals than early 2025. The full-year comparison is clear: deal count slipped only modestly from 24 in 2024 to 22 in 2025, while capital fell from about $729M to about $365M. That makes the reset primarily a round-size story.
Average round size fell from about $30M in 2024 to about $17M in 2025. Median round size fell even more sharply, from about $23M to about $9M. The median matters because it tells us what the typical funded company actually experienced, without being distorted by a few large rounds.
Early 2026 is different. The market has 10 deals and about $114M of capital, versus 5 deals and about $62M in the comparable 2025 period. That improvement is partly a deal-count rebound, but it still depends on a small number of meaningful mid-sized fermentation rounds.
So the practical reading is split. The 2024-to-2025 decline was driven by smaller rounds. The early 2026 improvement is driven by more fundable companies and a few larger technical rounds, not by a full return to large-scale alternative protein financing.
For deeper benchmarks on deal sizes, medians and round distributions, see the alternative protein market deck.
Is alternative protein capital moving toward later-stage or earlier-stage companies?
Alternative protein capital is moving away from late-stage scale-up financing and toward earlier and mid-stage validation. In 2024, Series B and later rounds captured about 73% of capital. In 2025, strict late-stage capital, meaning Series C and later plus growth equity, fell to about 38% of total capital. So far in 2026, there have been no eligible Series C, Series D+ or growth equity rounds.
The 2024 market still had a meaningful scale-up layer. Series B alone captured about $343M, or 47% of all 2024 capital, while Series C and growth equity added another $190M. That financing structure looked like a market still willing to back expansion-stage companies.
By 2025, the center of gravity shifted. Series A became the largest stage by dollars, with about $108M, and Series B represented about $77M. Growth equity remained visible, but there was only one Series C round and one Series D+ round.
So far in 2026, Seed and Series A together account for about $63M, while Series B+ accounts for about $29M among assignable stages. The absence of later rounds matters because it shows that investors are willing to fund validation, but not yet willing to reopen the very large commercialization checks that defined the earlier alternative protein cycle.
The best interpretation is that capital is moving toward companies that have passed initial science risk but do not yet require massive scale-up financing. The alternative protein market is funding proof, not unchecked expansion.
This chart, featured in our alternative protein market deck, compares the main business model options for alternative protein brands
Is the alternative protein market maturing or still experimental?
The alternative protein market is maturing inside a narrower opportunity set, but it is still experimental across much of the category map. The clearest maturity signal is that most capital goes to follow-on companies, not brand-new startups. Follow-on companies captured roughly 97% of capital in 2024, about 98% in 2025, and about 98% so far in 2026.
That is not a formation boom. It is a selective survival market. Investors are backing companies that already passed earlier diligence filters, especially those with technical proof, regulatory progress, strategic relationships or commercialization milestones.
The category mix also points toward maturation. Fermentation proteins captured the majority of capital in every period reviewed, and in year-to-date 2026 they captured about 78% of all disclosed funding. This suggests the market is becoming more technical and less brand-led.
But the market is not fully mature. A mature market would show broader late-stage financing, more predictable scale-up capital and less dependence on a few top rounds. Instead, there have been no eligible $100M-plus equity rounds in 2024, 2025 or year-to-date 2026, and concentration remains very high.
The right reading is that the alternative protein market is maturing around fermentation proteins, functional ingredients and differentiated food-system inputs. Cultivated meat, cultivated seafood, plant-based eggs and conventional plant-based dairy still look more experimental or capital-constrained.
Are new startups still entering the alternative protein market?
New startups are still entering the alternative protein market, but new-company formation is weak and lightly funded compared with follow-on activity. In 2024, first financings represented about 21% of deals but only about 3% of capital. In 2025, first financings fell to about 9% of deals and about 2% of capital. So far in 2026, there has been only one first financing out of 10 deals, also representing about 2% of capital.
The full-year comparison is the cleaner read because first financings are naturally lumpy. In 2024, the market still showed some formation across fermentation, plant-based meat and cultivated meat. But even then, the capital attached to new startups was small.
In 2025, new startup entry became thinner. Those Vegan Cowboys and Atlantic Fish Co. were the only first financings in the eligible set, and together they accounted for only about $8M out of $365M. That is a small formation layer for a market built around technical experimentation.
So far in 2026, The Bland Company is the only true first financing, and it sits in plant-based egg-replacement proteins. That is an interesting signal because egg replacement remains an open functionality problem, but it does not change the broader conclusion.
The alternative protein market is not closed to new entrants, but it strongly favors companies that already have technical progress, investor history, strategic relationships or commercialization proof.
For the broader view across new entrants, follow-on rounds and category formation, see the full alternative protein market report.
Are more investors entering the alternative protein market?
More investors do not appear to be entering the alternative protein market in a broad-based way. The better interpretation is that the market is being supported by a narrower set of specialized, strategic and mission-aligned investors. The unique disclosed investor count fell from approximately 98 in 2024 to approximately 55 in 2025, while unique tier-1 investor count fell from 41 to about 33.
The year-to-date 2026 signal looks healthier on the surface, with about 46 disclosed investors across 10 deals. But that number should not be overread. Several 2026 rounds are syndicate-heavy fermentation deals, and a large number of named participants across a few rounds does not prove broad investor re-entry.
Repeat-investor activity is more revealing. In 2024, Lowercarbon Capital appeared in 3 deals, while REWE Group, Betagro Ventures, FoodLabs, Unovis, M Ventures and Nourish Ventures each appeared in 2. In 2025, repeat activity shifted toward Invest-NL, Unovis, APG/ABP, Novo Holdings, BOM and PeakBridge.
So far in 2026, only Astanor and Good Startup appear in more than one eligible deal. That suggests the market is carried by informed conviction capital rather than a large wave of new generalist venture investors.
The conclusion is that investor entry is not broadening in a durable way. Alternative protein still attracts capital, but the investor base is more selective, more specialized and more tied to strategic or sector-focused conviction.
This chart, featured in our alternative protein market deck, shows annual funding in alternative protein startups
Are top investors getting more or less active in alternative protein?
Top investors are getting more selective rather than more broadly active in the alternative protein market. In 2024, repeat investors were spread across fermentation, plant-based meat and adjacent platforms. In 2025, repeat activity shifted toward European and food-tech specialists. So far in 2026, only Astanor and Good Startup appear more than once in the eligible dataset.
This is not a simple story of top investors leaving the market. Names such as Sofinnova, Bpifrance, Danone Ventures, Bel Group, Oetker Ventures, S2G, Unovis, AgFunder and Initialized still appear in individual 2026 rounds. The issue is that few of them are making repeated commitments in the current year-to-date window.
The 2025 pattern is important because it shows how top-investor activity changed. Invest-NL and Unovis each appeared in 3 deals, while APG/ABP, Novo Holdings, BOM and PeakBridge appeared in 2. That is a more European, institutional and strategically aligned investor base than the broader foodtech enthusiasm of earlier cycles.
The strongest conclusion is that top investors are not getting broadly more active. They are becoming more discriminating, backing fermentation, functional ingredients, differentiated plant-based meat and supply-chain-relevant platforms rather than the alternative protein category as a generic theme.
Which alternative protein subcategories are gaining momentum?
Fermentation proteins are clearly gaining the most momentum in the alternative protein market. They captured about 56% of full-year 2025 capital and then jumped to about 78% of year-to-date 2026 capital. That is the clearest capital-allocation signal in the dataset.
The momentum is not just about frequency. Fermentation proteins had 50% of deals and 66% of capital in 2024, 41% of deals and 56% of capital in 2025, and 50% of deals but 78% of capital so far in 2026. The capital-share-to-deal-share ratio rose from 1.33x to 1.36x to 1.57x, which means investors are writing larger checks to fermentation companies than to the average alternative protein company.
Within fermentation, dairy proteins, casein, beta-lactoglobulin, mycoprotein and B2B protein ingredients look especially strong. Verley, Standing Ovation, Planetary, Those Vegan Cowboys and AuX Labs all point to the same theme: the strongest companies are solving protein functionality and industrial supply problems, not just launching new consumer brands.
Plant-based eggs are also showing a small formation signal. There were no qualifying plant-based egg deals in 2024, UMAMI UNITED raised about $2M in 2025, and The Bland Company raised about $2.67M in year-to-date 2026. The dollars are small, but the category remains fundable when framed as functionality.
Plant-based meat is not gaining broad momentum, but differentiated plant-based meat is still alive. Texture technology, localized taste, foodservice relevance and manufacturing advantage matter more than simply being another substitute meat brand.
We cover these subcategory shifts in more detail in the market report covering alternative protein subcategories.
Which alternative protein subcategories are losing momentum?
Cultivated meat, cultivated seafood and conventional plant-based dairy are losing momentum or remain severely capital-constrained in the alternative protein market. Cultivated meat fell from about $98M in 2024 to about $25M in 2025, and only $6M so far in 2026. That is not abandonment, but it is financial rationing.
Cultivated meat still receives support for selected companies such as Mosa Meat, Aleph Farms, Prolific Machines and Evergreen Select. But the round sizes are not consistent with a broad scale-up financing boom. Investors are keeping the category alive without aggressively funding commercialization at scale.
Cultivated seafood looks even weaker under this screen. There were no qualifying cultivated seafood deals in 2024, one small $1.2M seed deal in 2025, and no qualifying year-to-date 2026 deals. That does not prove the category has no technical promise, but it does show no current scale-financing signal in disclosed equity funding.
Plant-based dairy is more nuanced. It captured about $40M in 2024, about $24M in 2025, and about $4M so far in 2026. Its capital-share-to-deal-share ratio stayed below parity in every period, which means it has deal presence but weak capital intensity.
The key distinction is that dairy alternatives are not weak when they are framed as fermentation-derived proteins. They are weak when they are framed as conventional plant-based dairy brands. Investors are moving away from another dairy substitute label and toward the protein layer behind dairy functionality.
This chart, featured in our alternative protein market deck, looks at Impossible Foods’ strategy in alternative protein
Which regions are gaining momentum in alternative protein funding?
Europe is the region gaining the most momentum in alternative protein funding. Europe captured about 41% of capital in 2024, about 66% in 2025, and about 79% so far in 2026. It also led deal count in every period reviewed.
This is not a one-off outlier. In 2024, North America still led by capital, but Europe already had more deals. In 2025, Europe overtook North America decisively, raising about $242M across 13 deals compared with North America’s about $113M across 6 deals.
So far in 2026, Europe’s lead is even stronger. It has raised about $91M across 6 of the 10 year-to-date deals. The European lead is especially tied to fermentation proteins, including Verley, Standing Ovation, Planetary, Those Vegan Cowboys and Mö Foods.
Asia-Pacific is also becoming more visible, but the signal is narrower. It had about 1% of 2025 capital and about 12% of year-to-date 2026 capital, largely because of Green Rebel’s $12.5M round. That is meaningful, but it is not yet broad regional capitalization.
For ongoing regional tracking across Europe, North America, Asia-Pacific and smaller emerging regions, see the full market view on alternative protein geography.
Which regions are losing momentum in alternative protein funding?
North America is losing relative momentum in the alternative protein market. It led 2024 by capital, with about 51% of total funding, then fell to about 31% in 2025 and about 9% so far in 2026. That is the clearest regional decline.
The decline is not only about deal count. North America raised about $373M across 9 deals in 2024, about $113M across 6 deals in 2025, and only about $10M across 2 deals so far in 2026. The average North American round also fell sharply across the same periods.
The full-year comparison is more reliable than the early 2026 read, but both point in the same direction. North American alternative protein companies still raise money, but the region no longer dominates the category the way it did when larger growth rounds were more common.
The Middle East also lost visible momentum, although the evidence is thin because the region was never broad in this dataset. It had one $17M deal in 2024, one $7M deal in 2025, and no qualifying year-to-date 2026 deals.
Latin America and Africa are not so much losing momentum as failing to show meaningful disclosed funding activity. Latin America had one very small 2024 deal, no qualifying 2025 deals and no qualifying year-to-date 2026 deals. Africa had no qualifying deals in the periods reviewed.
Is the alternative protein market becoming more global or more regionally concentrated?
The alternative protein market is becoming more regionally concentrated, not more global in a balanced way. Europe’s capital share rose from about 41% in 2024 to about 66% in 2025 and about 79% so far in 2026. Over the same periods, North America’s share fell from about 51% to about 31% and then about 9%.
A market that is becoming more global should show broader capital distribution across North America, Europe, Asia-Pacific, Latin America, Africa and the Middle East. The alternative protein market is instead consolidating around Europe, with selective activity elsewhere.
In 2024, disclosed activity appeared across North America, Europe, Asia-Pacific, the Middle East and Latin America. That was the most geographically diverse period in the dataset. Europe and North America dominated, but smaller regions were at least visible.
By 2025, Europe and North America together captured about 97% of capital. So far in 2026, Europe, Asia-Pacific and North America are the only active regions, and Europe alone has nearly 80% of funding.
The answer is assertive: the alternative protein market is not globalizing evenly. It is becoming Europe-centered, with smaller pockets of activity in Asia-Pacific and North America.
This chart, featured in our alternative protein market deck, shows how progress toward price parity has driven growth in the alternative protein market over time
Is alternative protein capital moving toward proven winners or new opportunities?
Alternative protein capital is moving decisively toward proven winners, with only small amounts reserved for new opportunities. Follow-on companies captured about 97% of capital in 2024, about 98% in 2025 and about 98% so far in 2026. First financings exist, but they are rare and small.
The first-financing split makes this very clear. First financings were about 21% of deals in 2024 but only about 3% of capital. They were about 9% of deals and about 2% of capital in 2025. So far in 2026, they are 10% of deals and about 2% of capital.
The stage mix supports the same conclusion. Seed rounds are visible, but the dollars are concentrated in companies that have already moved beyond the first proof point. Even in 2026, where Seed represents 40% of deals, Seed rounds capture only about 12% of capital.
The category pattern also shows a preference for proven winners. Fermentation proteins dominate because investors can underwrite specific milestones such as protein functionality, production scale-up, regulatory readiness and B2B demand.
The alternative protein market has shifted from opportunity discovery to survivor selection. New opportunities are still visible in plant-based eggs, cultivated seafood and localized plant-based meat, but the bulk of capital flows to companies with prior validation.
The deeper analysis of the alternative protein market tracks these follow-on patterns across companies, categories and stages.
Is the alternative protein market becoming winner-takes-most?
The alternative protein market is becoming more winner-takes-most in capital allocation, but not because one company dominates the entire market. The better interpretation is that capital is concentrating among a small set of credible companies and technical platforms.
The concentration numbers show the pattern. The top 10 rounds captured about 77% of 2024 capital, about 86% of 2025 capital, and 100% of year-to-date 2026 capital because there have only been 10 deals. The bottom half of deals captured about 16% of capital in 2024, about 11% in 2025 and about 14% so far in 2026.
The largest-round-to-median-round ratio also shows inequality. It was about 4.4x in 2024, 6.2x in 2025 and 4.7x so far in 2026. That means the biggest winners raise several times more than a typical funded company, even in years without $100M-plus rounds.
This is not a pure monopoly dynamic. The winning group changes across years, and the top companies are spread across fermentation, plant-based meat, cultivated meat and dairy proteins. But capital is definitely concentrating into fewer companies that investors believe can clear technical and commercial hurdles.
The practical rule is to separate deal count from economic weight. A category can appear active while most dollars still go to a small number of technical winners.
Is the next wave of alternative protein winners becoming visible?
The next wave of alternative protein winners is becoming visible, but it is appearing earlier in the food-system stack than in retail. The likely winners are emerging around proteins, ingredients, fermentation platforms and manufacturing capabilities before they become obvious as consumer brands.
In year-to-date 2026, the strongest funded companies include Verley, Standing Ovation, Planetary, Those Vegan Cowboys and AuX Labs. These are not conventional supermarket challenger brands. They are built around beta-lactoglobulin, casein, mycoprotein, fermentation infrastructure or animal-free dairy functionality.
The same logic appears in plant-based categories. Green Rebel matters because it is culturally localized and Asia-focused. The Bland Company matters because it tackles egg functionality from sidestream proteins. These companies are not simply saying “replace meat” or “replace eggs.” They are attacking specific bottlenecks.
The next wave is therefore more technical, more B2B and more integrated with existing food systems. Companies that can plug into cheese, bakery, meat-processing, foodservice or ingredient supply chains look more financeable than companies that require consumers to adopt entirely new eating behaviors.
The unresolved question is whether these mid-sized technical winners can graduate into late-stage scale-up rounds. Until that happens, the next wave is visible, but not yet fully validated as a large-scale financing cycle.
As this chart shows, and as featured in our alternative protein market deck, search interest in pea protein has been growing steadily
Is the alternative protein funding landscape fragmenting or consolidating?
The alternative protein funding landscape is consolidating economically while remaining diverse taxonomically. Many categories still show some activity, but fermentation proteins and Europe absorb the economic center of gravity. That means the market looks broad on a category map but narrow when measured by dollars.
In year-to-date 2026, fermentation proteins account for 50% of deals and about 78% of capital. Europe accounts for 60% of deals and about 79% of capital. Those two concentration patterns reinforce each other because Europe’s rise is closely tied to fermentation and dairy-protein activity.
Investor concentration is also visible, but it is not dominated by one fund. The market does not have a single equivalent of a category kingmaker. Instead, it has a recurring group of food-tech specialists, strategics, climate funds, sovereign or semi-public investors and sector-focused funds.
The right description is asymmetric. The alternative protein market is fragmented across technologies and regions in theory, but consolidated around a small number of technical bottlenecks in practice. Fermentation proteins, protein functionality, cost progress and manufacturing scale are where the market is concentrating.
Where is investor attention shifting in alternative protein?
Investor attention in the alternative protein market is shifting toward specific bottleneck solutions rather than generic replacement narratives. The strongest deals solve protein functionality, price-performance, manufacturing scale, regulatory readiness or supply-chain volatility.
The biggest rounds in year-to-date 2026 make this clear. Verley is about beta-lactoglobulin and dairy-protein functionality. Standing Ovation is about casein and commercial food applications. Planetary is about mycoprotein and fermentation capacity. AuX Labs is about recombinant casein for animal-free cheese.
This is a different market from the earlier consumer-brand cycle. Investors are not simply asking whether a product can replace meat, milk or eggs. They are asking whether the company can become useful infrastructure for the food industry.
Strategic validation matters more in this cycle. Corporate food investors, food-sector specialists, climate funds, sovereign or semi-public investors and industrial partners carry more signal than broad participation from non-specialist venture funds.
The most useful lens is therefore not “alternative protein versus conventional protein.” It is “which alternative protein companies solve a constraint that existing food companies already care about?” That is where investor attention is moving.
For real-time tracking of how attention is moving across fermentation proteins, plant-based meat, plant-based dairy, eggs, cultivated meat and cultivated seafood, see the full alternative protein market report.
All the funding deals in the alternative protein market from 2024 to April 2026
The table below lists every disclosed equity round in the supplied alternative protein funding dataset from January 2024 to April 2026, covering companies across fermentation proteins, plant-based meat, plant-based dairy, plant-based eggs, cultivated meat, and cultivated seafood.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader investability view, see our market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| AuX Labs | Apr 2026 | Canadian precision-fermentation company developing recombinant casein for animal-free cheese. | Fermentation Proteins | Unknown | $4M | North America | Follow-on | None clearly identified | Green Queen |
| Planetary | Apr 2026 | Swiss fermentation company selling mycoprotein as a B2B ingredient and licensing fermentation infrastructure for alt-meat, hybrid meat, dairy, and protein-fortification applications. | Fermentation Proteins | Series A | $20M | Europe | Follow-on | Astanor Ventures; Oetker Ventures | AgFunderNews |
| Standing Ovation | Mar 2026 | French precision-fermentation company producing casein and dairy proteins for commercial food applications. | Fermentation Proteins | Series B | $28.5M | Europe | Follow-on | Bpifrance; Astanor; Bel Group; Danone Ventures | EU-Startups |
| Those Vegan Cowboys | Mar 2026 | Dutch precision-fermentation company developing animal-free casein for cheese and dairy applications. | Fermentation Proteins | Seed | $6.9M | Europe | Follow-on | None clearly identified | Green Queen |
| Verley | Feb 2026 | French precision-fermentation company producing beta-lactoglobulin whey proteins for dairy and high-protein food applications. | Fermentation Proteins | Series A | $30M | Europe | Follow-on | Sofinnova | AgFunderNews |
| The Bland Company | Feb 2026 | UK protein-science startup transforming agricultural sidestream proteins into functional egg-replacement proteins. | Plant Based Eggs | Seed | $2.67M | Europe | First financing | Initialized Capital | AgFunderNews |
| Green Rebel Foods | Feb 2026 | Indonesian plant-based meat company making Asian-style meat alternatives such as beefless rendang and satay. | Plant Based Meat | Unknown | $12.5M | Asia-Pacific | Follow-on | Unovis; AgFunder | Asia Business Outlook |
| 1.5 Degree | Feb 2026 | Indian plant-based dairy platform focused on institutional foodservice, including gelatos, frozen desserts, smoothie bowls, and oat-milk beverages. | Plant Based Dairy | Seed | $1M | Asia-Pacific | Follow-on | None clearly identified | FNB News |
| Evergreen Select, formerly Omeat | Feb 2026 | Cultivated beef platform focused on blended beef products and supply-chain stability. | Cultivated Meat | Unknown | $6M | North America | Follow-on | S2G Investments | Business Wire |
| Mö Foods | Jan 2026 | Finnish producer of oat-based cheese alternatives designed to match dairy cheese taste, texture, and meltability. | Plant Based Dairy | Seed | $2.6M | Europe | Follow-on | None clearly identified | Vegconomist |
| Mosa Meat | Dec 2025 | Cultivated beef. | Cultivated Meat | Unknown | $17.6M | Europe | Follow-on | M Ventures | M Ventures |
| Those Vegan Cowboys | Dec 2025 | Precision-fermented cow-free casein for animal-free dairy. | Fermentation Proteins | Seed | $6.9M | Europe | First financing | Novo Holdings; Blue Horizon | Protein Production Technology |
| Ripple Foods | Dec 2025 | Pea-based dairy alternatives including milk and shakes. | Plant Based Dairy | Growth Equity | $17M | North America | Follow-on | None newly disclosed | PR Newswire |
| Atlantic Fish Co. | Nov 2025 | Cultivated whitefish and cultivated seafood products. | Cultivated Seafood | Seed | $1.2M | North America | First financing | Katapult Ocean | Atlantic Fish Co. |
| The EVERY Company | Oct 2025 | Precision-fermented egg proteins. | Fermentation Proteins | Series D+ | $55M | North America | Follow-on | McWin Food Tech Fund | Business Wire |
| UMAMI UNITED | Oct 2025 | Plant-based egg ingredients replicating egg functions. | Plant Based Eggs | Seed | $2M | Asia-Pacific | Follow-on | Beyond Next Ventures; Genesia Ventures; MUFG / Mitsubishi UFJ Capital; Mizuho Capital | Protein Production Technology |
| Nutropy | Oct 2025 | Precision-fermented casein and milk proteins for animal-free cheese. | Fermentation Proteins | Unknown | $8.1M | Europe | Follow-on | Heartcore Capital; Big Idea Ventures | Green Queen |
| MATR Foods | Oct 2025 | Fermentation-based organic plant-based meat alternatives. | Plant Based Meat | Series A | $21.6M | Europe | Follow-on | Unovis; PeakBridge | PR Newswire |
| Bettani Farms | Oct 2025 | Seed-derived Caseed protein for dairy-free cheese. | Plant Based Dairy | Series A | $6.5M | North America | Follow-on | S2G Ventures; Manta Ray Ventures | PR Newswire |
| Revyve | Sep 2025 | Yeast proteins replacing eggs and additives in bakery, sauces, alt-meat, and plant-based dairy. | Fermentation Proteins | Series B | $28M | Europe | Follow-on | Invest-NL; Unovis; ABN AMRO Sustainable Impact Fund | Revyve |
| The Protein Brewery | Sep 2025 | Fungi-derived Fermotein ingredient for meat, dairy alternatives, and nutrition products. | Fermentation Proteins | Series B | $35.6M | Europe | Follow-on | Novo Holdings; Invest-NL; Unovis | The Protein Brewery |
| Nxtfood / ACCRO | Sep 2025 | Plant-based meat products sold under the ACCRO brand. | Plant Based Meat | Growth Equity | $58M | Europe | Follow-on | Creadev; Roquette Ventures; Clay Capital | AgFunderNews |
| The Better Meat Co. | Aug 2025 | Rhiza mycoprotein ingredient platform for meat alternatives and blended products. | Fermentation Proteins | Series A | $31M | North America | Follow-on | Future Ventures; Resilience Reserve | AgFunderNews |
| Better Nature | Aug 2025 | Tempeh products positioned as alternatives to chicken. | Plant Based Meat | Seed | $1.5M | Europe | Follow-on | None disclosed | Green Queen |
| Rival Foods | Jun 2025 | Whole-cut plant-based meat for foodservice, retail, and brands. | Plant Based Meat | Series B | $10.7M | Europe | Follow-on | APG/ABP; PeakBridge | Rival Foods |
| NoMy | May 2025 | Mycoprotein technologies using sidestreams for sustainable protein alternatives. | Fermentation Proteins | Unknown | $1.4M | Europe | Follow-on | Nippon Beet Sugar Manufacturing; EIT Food | EU-Startups |
| High Time Foods | May 2025 | Shelf-stable plant-based protein products positioned for affordable meat/protein substitution. | Plant Based Meat | Seed | $1.2M | Asia-Pacific | Follow-on | Avaana Capital | Protein Production Technology |
| Aleph Farms | Mar 2025 | Cultivated beef steaks and cultivated meat production technology. | Cultivated Meat | Series C | $7M | Middle East | Follow-on | None newly disclosed | AgFunderNews |
| Vivici | Feb 2025 | Precision-fermented dairy proteins, including beta-lactoglobulin and lactoferrin. | Fermentation Proteins | Series A | $33.7M | Europe | Follow-on | APG/ABP; Invest-NL; dsm-firmenich; Fonterra | Vivici |
| Kynda | Feb 2025 | Mycoprotein made from upcycled food waste for alternative meat applications. | Fermentation Proteins | Seed | $3.2M | Europe | Follow-on | PHW Group | Green Queen |
| Project Eaden | Jan 2025 | Ultra-realistic plant-based meat using fiber-spinning technology. | Plant Based Meat | Series A | $15.6M | Europe | Follow-on | Planet A; REWE Group; DeepTech & Climate Fonds; Creandum | DeepTech & Climate Fonds |
| Rebellyous Foods | Jan 2025 | Plant-based chicken products and automated manufacturing system for plant-based chicken. | Plant Based Meat | Series B | $2.4M | North America | Follow-on | None disclosed | GeekWire |
| Peruvian Veef | Dec 2024 | Affordable locally made plant-based meat products in Peru. | Plant Based Meat | Seed | $0.32M | Latin America | First financing | Sustainable Food Ventures | Vegconomist |
| Plantible Foods | Nov 2024 | Duckweed-derived Rubi Protein ingredient for food applications. | Fermentation Proteins | Series B | $30M | North America | Follow-on | Siddhi Capital; Astanor Ventures | PR Newswire |
| Happy Plant Protein | Nov 2024 | VTT spinout licensing technology to produce high-quality plant proteins using existing extrusion machinery. | Plant Based Meat | Seed | $1.94M | Europe | First financing | Nordic Foodtech VC | Vegconomist |
| Shiru | Nov 2024 | AI-powered discovery of functional proteins and sustainable food ingredients. | Fermentation Proteins | Series B | $16M | North America | Follow-on | S2G Ventures; Lux Capital | PR Newswire |
| La Vie | Oct 2024 | Plant-based pork, bacon and deli meats. | Plant Based Meat | Unknown | $26.5M | Europe | Follow-on | Zintinus | Vegconomist |
| Helaina | Sep 2024 | Precision-fermented human-equivalent bioactive dairy proteins, starting with lactoferrin. | Fermentation Proteins | Series B | $45M | North America | Follow-on | Spark Capital; Primary Venture Partners | Business Wire |
| Novameat | Sep 2024 | Whole-cut plant-based chicken, beef and turkey. | Plant Based Meat | Series A | $19.2M | Europe | Follow-on | Sofinnova Partners; Forbion; Unovis | Vegconomist |
| Formo | Sep 2024 | Fermentation-derived and koji-protein animal-free cheese alternatives. | Fermentation Proteins | Series B | $61M | Europe | Follow-on | EQT Ventures; Lowercarbon Capital; M Ventures | M Ventures |
| Meat Tomorrow | Sep 2024 | Pluripotent stem-cell lines for cultivated meat. | Cultivated Meat | Seed | $0.607M | Europe | First financing | Accelerace | NewTechFoods |
| New School Foods | Aug 2024 | Plant-based whole-cut salmon. | Plant Based Meat | Seed | $6M | North America | Follow-on | Good Startup | Vegconomist |
| NovoNutrients | Jul 2024 | CO2 and hydrogen fermentation into Novotein protein ingredient. | Fermentation Proteins | Series A | $18M | North America | Follow-on | CM Venture Capital | FoodBev |
| Oatside | Jun 2024 | Oat milk and plant-based dairy beverages. | Plant Based Dairy | Series B | $35.3M | Asia-Pacific | Follow-on | Granite Asia | Green Queen |
| Tender Food | Jun 2024 | Fiber-spun plant-based meat and seafood analogues. | Plant Based Meat | Series A | $11M | North America | Follow-on | Lowercarbon Capital | Green Queen |
| Prolific Machines | Jun 2024 | Photomolecular biology platform to control cell growth for cultivated meat and biomanufactured proteins. | Cultivated Meat | Series B | $55M | North America | Follow-on | SOSV; In-Q-Tel | AgFunderNews |
| Meati Foods | May 2024 | Mycelium-based whole-food meat alternatives. | Fermentation Proteins | Series C | $100M | North America | Follow-on | Grosvenor Food & AgTech; Prelude Ventures; Bond | Green Queen |
| Maia Farms | May 2024 | Mycelium biomass fermentation ingredients and blended mycelium/plant protein. | Fermentation Proteins | Seed | $1.7M | North America | First financing | Joyful Ventures | AgFunderNews |
| Mosa Meat | Apr 2024 | Cultivated beef. | Cultivated Meat | Unknown | $42.4M | Europe | Follow-on | Lowercarbon Capital; M Ventures | M Ventures |
| Onego Bio | Apr 2024 | Animal-free egg protein, Bioalbumen, made by precision fermentation. | Fermentation Proteins | Series A | $30M | Europe | Follow-on | NordicNinja; Agronomics | Onego Bio |
| ProteinDistillery | Mar 2024 | Upcycled brewer’s yeast protein ingredients for clean-label meat and food alternatives. | Fermentation Proteins | Seed | $16.3M | Europe | First financing | Green Generation Fund | ProteinDistillery |
| Miruku | Feb 2024 | Molecular farming platform for dairy proteins and fats in plants. | Plant Based Dairy | Series A | $5M | Asia-Pacific | Follow-on | Movac | TechCrunch |
| Heura Foods | Feb 2024 | Plant-based meat and adjacent plant-based food products. | Plant Based Meat | Series B | $43M | Europe | Follow-on | Unovis; ECBF | ECBF |
| Infinite Roots | Jan 2024 | Mycelium fermentation products for food. | Fermentation Proteins | Series B | $58M | Europe | Follow-on | EIC Fund; FoodLabs | Infinite Roots |
| The Mediterranean Food Lab | Jan 2024 | Solid-state fermentation flavor ingredients that improve plant-based meat and alt-meat products. | Fermentation Proteins | Series A | $17M | Middle East | Follow-on | Gullspång Re:food; PeakBridge | Vegconomist |
| Perfect Day | Jan 2024 | Animal-free dairy proteins made by precision fermentation. | Fermentation Proteins | Growth Equity | $90M | North America | Follow-on | Temasek/Horizons-linked board representation; internal investors not fully disclosed | Food Business News |
INSIGHTS
The insights below come from reviewing disclosed equity rounds in the alternative protein market between January 2024 and May 2026, using the same pure-play, $300K-plus, disclosed-amount funding screen across plant-based meat, plant-based dairy, plant-based eggs, fermentation proteins, cultivated meat and cultivated seafood.
- The alternative protein market is no longer best understood as one market. The evidence points to at least two markets: a financeable fermentation-and-functional-ingredients market, and a much weaker consumer-substitution market.
- Fermentation proteins are the strongest repeated signal in the dataset. They repeatedly capture a larger share of dollars than deals, which means investors are assigning the category higher conviction per company.
- Full-year 2025 is the structural reset year. The market did not stop producing deals, but total capital fell by about half and median round size collapsed, showing that the reset happened through smaller checks rather than total market shutdown.
- Early 2026 looks healthier than early 2025, but the improvement is not yet a broad recovery. The top three 2026 rounds account for nearly 69% of capital, so the rebound depends heavily on a few companies.
- The market has shifted from category creation to proof filtering. Investors are no longer rewarding participation in the alternative protein theme; they are rewarding evidence of functionality, manufacturability, cost progress and channel relevance.
- First financings are the clearest weakness in the market. Across the periods reviewed, first financings represent a small share of deals and a tiny share of capital, which suggests limited new-company formation and a strong bias toward survivors.
- The apparent breadth of the market is misleading. Plant-based eggs, cultivated seafood and plant-based dairy appear in the category map, but they remain small capital pools compared with fermentation proteins.
- The decline in $50M-plus rounds is more important than the decline in deal count. There were five $50M-plus rounds in 2024, two in 2025 and none so far in 2026, which shows how much scale-up financing has cooled.
- Europe’s rise is institutional, not just geographic. The repeated presence of investors such as Invest-NL, Bpifrance, APG/ABP, BOM, Novo Holdings and strategic food investors suggests Europe’s edge is tied to mission-aligned and semi-strategic capital structures.
- North America’s decline is relative, not absolute abandonment. North American companies still raise money, but the region no longer dominates the category the way it did when larger growth rounds were more common.
- Plant-based meat is not dead; generic plant-based meat is weak. Companies that still attract funding tend to have texture technology, localized taste, foodservice relevance or manufacturing advantages.
- Plant-based dairy is being outcompeted for investor attention by fermentation-derived dairy proteins. The market appears more willing to fund the protein layer behind dairy functionality than another plant-based dairy brand.
- Cultivated meat remains credible but financially rationed. The category still receives follow-on support, but round sizes are not consistent with aggressive near-term scale-up.
- Cultivated seafood has the weakest evidence base among the listed categories. One small 2025 seed round and no qualifying 2024 or year-to-date 2026 funding means there is no current scale-financing signal.
- The strongest funded companies increasingly look like suppliers to the food industry rather than challengers trying to replace the food industry. Ingredient, protein and platform companies fit the current investor mood better than standalone consumer brands.
- The median round size is a better market-health indicator than total funding. Total funding can be lifted by a few large rounds, while the median shows what a typical funded company can actually raise.
- The market is becoming more evidence-sensitive. Sustainability or animal-replacement claims are no longer enough; investors appear to require proof of taste, cost, scale, functionality or near-term commercial demand.
- Regional concentration and category concentration reinforce each other. Europe’s rise is strongly connected to fermentation and dairy-protein activity, so the regional shift is also a technology-platform shift.
- The next wave of winners is visible earlier in the stack than in retail. The likely winners are emerging around proteins, ingredients and manufacturing capabilities before they are obvious as consumer brands.
- The biggest unresolved question is whether today’s mid-sized fermentation and functional-ingredient rounds can graduate into late-stage scale-up rounds without reviving the overcapitalized hype dynamics of the previous cycle.
This chart, featured in our alternative protein market deck, shows how plant-based meat product technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this alternative protein funding tracker by reviewing publicly disclosed equity rounds raised by pure-play alternative protein companies between January 2024 and May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to substitute proteins for conventional meat, seafood, dairy or eggs.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt, structured financings, credit lines, SPAC transactions, acquisitions and business combinations are excluded unless the source clearly identifies an eligible equity component. Second, we only counted rounds of $300K or more. Third, we only kept pure-play companies in plant-based meat, plant-based dairy, plant-based eggs, fermentation proteins, cultivated meat or cultivated seafood. And fourth, every entry had to be confirmed by a direct company announcement, press release, tier-1 media report, specialized industry source or relevant regional publication.
When a financing package mixed equity with grants, debt, credit or other non-dilutive funding, we counted only the equity component when the source separated it clearly. Undisclosed-amount rounds were excluded because including them would distort dollar-based metrics such as total capital, average round size, median round size and category share.
We also excluded adjacent companies that would have distorted the market definition, including generic foodtech ingredients not clearly replacing meat, seafood, dairy or eggs, pet-food companies, fat or oil substitutes outside the protein scope, infrastructure-only companies that do not themselves produce substitute proteins, and broader nutrition or biomolecule companies where alternative protein did not represent more than 80% of activity. The final dataset contains disclosed eligible rounds only, so private unannounced financings and database-only filings are necessarily outside the tracker.
Related blog posts
- What is new in the alternative protein market?
- What is the latest news in the alternative protein market?
- What is the actual size of the alternative protein market?
- The latest funding news in the alternative protein market
- How funding activity has evolved in the alternative protein market
- Which companies have raised the most funding in the alternative protein market?
- Which companies are the most valued in the alternative protein market?
